55
Participants
Start Date
May 2, 2017
Primary Completion Date
August 31, 2018
Study Completion Date
April 2, 2025
Irinotecan (CPT-11) liposome
"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered 50 mg/m2 on D1 of a 14-day cycle in monotherapy."
Hospital Universitario Virgen de Las Nieves, Granada
Hospital Universitario Clinico San Cecilio, Granada
ICO, Badalona
IOB Institute of Oncology - Quirón Barcelona, Barcelona
H. Ruber Juan Bravo, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Doce de Octubre, Madrid
Hospital Universitario Ramón y Cajal, Madrid
MD Anderson Madrid, Madrid
Hospital Clínico Virgen de la Victoria, Málaga
Hospital Universitari Son Espases, Palma de Mallorca
Son Llatzer, Palma de Mallorca
Sant Joan de Reus, Reus
Hospital Universitario Virgen del Rocío, Seville
IVO, Valencia
H. Miguel Servet, Zaragoza
MedSIR
OTHER